{"title":"阿达木单抗治疗耐药性软骨病","authors":"Fatih Tastekin, Kenan Aksu","doi":"10.1016/j.reuma.2024.06.003","DOIUrl":null,"url":null,"abstract":"<div><div>In this article, we present a case of resistant chondrocalcinosis who had a good response with 40<!--> <span>mg subcutaneous adalimumab<span><span>. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in </span>CPPD.</span></span></div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 452-453"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adalimumab treatment of resistant chondrocalcinosis\",\"authors\":\"Fatih Tastekin, Kenan Aksu\",\"doi\":\"10.1016/j.reuma.2024.06.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>In this article, we present a case of resistant chondrocalcinosis who had a good response with 40<!--> <span>mg subcutaneous adalimumab<span><span>. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in </span>CPPD.</span></span></div></div>\",\"PeriodicalId\":47115,\"journal\":{\"name\":\"Reumatologia Clinica\",\"volume\":\"20 8\",\"pages\":\"Pages 452-453\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia Clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1699258X24000718\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X24000718","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Adalimumab treatment of resistant chondrocalcinosis
In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD.
期刊介绍：
Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
